loading page

Psychotropic medication in pregnancy and lactation and early development of exposed children
  • +5
  • Anna Linda Leutritz,
  • Lara van Braam,
  • Katharina Preis ,
  • Andrea Gehrmann,
  • Maike Scherf-Clavel,
  • Katrin Fiedler,
  • Stefan Unterecker,
  • Sarah Kittel-Schneider
Anna Linda Leutritz
University Hospital of Würzburg

Corresponding Author:leutritz_a@ukw.de

Author Profile
Lara van Braam
University Hospital of Würzburg
Author Profile
Katharina Preis
Hospital of the Goethe University Frankfurt
Author Profile
Andrea Gehrmann
University Hospital of Würzburg
Author Profile
Maike Scherf-Clavel
Author Profile
Katrin Fiedler
Hospital of the Goethe University Frankfurt
Author Profile
Stefan Unterecker
Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital of Würzburg
Author Profile
Sarah Kittel-Schneider
University Hospital of Würzburg
Author Profile

Abstract

Aim There is still only little knowledge about alterations of blood concentrations of psychotropic drugs during pregnancy, the transfer of psychotropic drugs into breast-milk and the effects on exposed children. Methods We investigated changes in concentrations of psychopharmacological medication during pregnancy and lactation in serum and breast milk at different time points in a naturalistic sample of 60 mothers and observed the development of the exposed children in the first 12 months. Results We found a decrease in serum concentrations from the first to the second trimester of amitriptyline, duloxetine, escitalopram, quetiapine and sertraline. Citalopram stayed rather stable during pregnancy, sertraline levels interestingly increased again from the second to the third trimester. Highest concentration-by-dose-ratios in breast milk were found for venlafaxine as well as lamotrigine, lowest for quetiapine and clomipramine. Similarly, clomipramine and quetiapine showed lowest milk/serum-penetration-ratios. Regarding the birth outcome measures in children we found no significant differences between in utero exposed compared to non-exposed new-borns. There were no significant differences in the development in the first 12 months. Conclusion Psychotropic medication in the peripartum needs a balancing of risks and benefits and a continuous therapeutic drug monitoring (TDM) can be a guidance for clinicians to monitor drug alteration patterns, which are likely to occur due to physiological pregnancy-associated changes in pharmacokinetics. Accordingly, TDM can optimize a medication in pregnancy and lactation with the lowest but effective dose.
08 May 2022Submitted to British Journal of Clinical Pharmacology
09 May 2022Submission Checks Completed
09 May 2022Assigned to Editor
17 Jun 2022Reviewer(s) Assigned
19 Jul 2022Review(s) Completed, Editorial Evaluation Pending
21 Jul 2022Editorial Decision: Revise Major
21 Aug 20221st Revision Received
22 Aug 2022Submission Checks Completed
22 Aug 2022Assigned to Editor
22 Aug 2022Review(s) Completed, Editorial Evaluation Pending
24 Aug 2022Reviewer(s) Assigned
06 Sep 2022Editorial Decision: Accept
03 Oct 2022Published in British Journal of Clinical Pharmacology. 10.1111/bcp.15533